Fianlimab Biosimilar – Anti-LAG3, CD223 mAb – Research Grade

Introduction

Fianlimab Biosimilar is an anti-LAG3, CD223 monoclonal antibody (mAb) that has been developed as a research grade therapeutic agent. It is a biosimilar version of the FDA-approved drug, Fianlimab, which is used to treat certain types of cancer. In this article, we will provide a scientific description of Fianlimab Biosimilar, including its structure, activity, and potential applications as an antibody and therapeutic target.

Structure

Fianlimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is composed of two identical heavy chains and two identical light chains. The heavy chains are approximately 50 kDa in size and consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH). The light chains are approximately 25 kDa in size and consist of two constant domains (CL and CL2) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the target antigen, LAG3.

Activity

Fianlimab Biosimilar works by binding to LAG3, which is a cell surface protein that is expressed on certain immune cells, including T cells, B cells, and natural killer cells. LAG3 is known to play a role in regulating immune responses, and its overexpression has been linked to various diseases, including cancer. By binding to LAG3, Fianlimab Biosimilar blocks its activity and prevents it from inhibiting the immune response. This allows for a more robust and effective immune response against cancer cells.

Additionally, Fianlimab Biosimilar has been shown to have an antibody-dependent cell-mediated cytotoxicity (ADCC) effect, where it can bind to cancer cells and activate immune cells to attack and kill them. This dual mechanism of action makes Fianlimab Biosimilar a potent and promising therapeutic agent for cancer treatment.

Applications as an Antibody

As an antibody, Fianlimab Biosimilar has a wide range of potential applications in both research and clinical settings. It can be used as a tool in various research studies to investigate the role of LAG3 in immune regulation and its potential as a therapeutic target. Fianlimab Biosimilar can also be used in diagnostic assays to detect the expression of LAG3 in different types of cancer and monitor its levels during treatment.

Therapeutic Target

As a therapeutic target, Fianlimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It has been shown to have a favorable safety profile and can be used in combination with other cancer therapies to enhance their efficacy. Fianlimab Biosimilar is currently being evaluated in several ongoing clinical trials, and it is expected to receive FDA approval in the near future.

Conclusion

In summary, Fianlimab Biosimilar is a research grade anti-LAG3, CD223 monoclonal antibody that has a complex structure and a dual mechanism of action. It has the potential to be used as an antibody in research studies and diagnostic assays, as well as a therapeutic target for the treatment of various types of cancer. With its promising results in clinical trials, Fianlimab Biosimilar is expected to be a valuable addition to the current arsenal of cancer therapies.